CorMedix Inc. (CRMD)
CorMedix Q1 Earnings Call Highlights
CorMedix NASDAQ: CRMD reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while management raised its full-year financial outlook and outlined key pipeline developments.
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.3 per share a year ago.
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
CorMedix (CRMD) Lags Q4 Earnings Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.61 per share, missing the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.22 per share a year ago.
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?
CorMedix heads into Q4 earnings with DefenCath sales, Melinta product contributions, and its muted 2026 guidance firmly in focus.
CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?
CRMD stock sinks 27% in 3 months as its bearish 2026 outlook for DefenCath clouds near-term growth, raising investor concern.
CorMedix Inc. (CRMD) Analyst/Investor Day Transcript
CorMedix Inc. (CRMD) Analyst/Investor Day Transcript
CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside
CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.
CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?
CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?
CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.
